AstraZeneca said its COVID-19 vaccine had a 76 per cent efficacy rate at preventing symptomatic illness in a new analysis of its major U.S. trial — slightly lower than the level announced earlier this week in a report that was criticized for using

This story was originally published on  CBC News. To read the rest of this news worthy story, please visit https://www.cbc.ca/news/world/astrazeneca-trial-efficacy-1.5963123?cmp=rss.

This post was originally published on this site